Abstract:Chronic hepatitis C virus (HCV) infection exerts its main effects on the liver, promoting hepatic inflammation and fibrosis and increasing the risk of cirrhosis, hepatic decompensation, and hepatocellular carcinoma [1]. However, chronic HCV infection also affects organ systems outside of the liver and can contribute to the development of a variety of extrahepatic diseases, most notably atherosclerosis, metabolic alterations (eg, insulin resistance, diabetes mellitus, hepatic steatosis), renal disease (eg, proteinuria, membranoproliferative glomerulonephritis), bone disease (eg, arthralgias, osteoporosis, fractures), neuropsychiatric manifestations (eg, fatigue, cognitive impairment), B-cell non-Hodgkin’s lymphoma, cutaneous disorders (eg, lichen planus, porphyria cutanea tarda), and autoimmune and immune-mediated conditions (eg, mixed cryoglobulinemia, thyroid disease, sicca syndrome) [2, 3]. Some studies have suggested that the incidence of these diseases might be higher for human immunodeficiency virus (HIV)/HCV–coinfected individuals than for those with HCV alone [4, 5]. Regardless of HIV status, HCV-related extrahepatic conditions contribute to morbidity and could increase the risk of nonliver-related mortality [6–9]. The mechanisms for the extrahepatic comorbidities associated with chronic HCV infection are incompletely understood but are likely multifactorial. HCV replication in extrahepatic cells, interactions between HCV proteins and intracellular signaling pathways, HCVinduced stimulation of B-lymphocytes, and immune activation leading to chronic inflammation have all been hypothesized to play a role in the development of these conditions [2, 3]. Lifestyle factors, such as drug and alcohol abuse, smoking, and poor nutrition, may also be important contributors to the development of HCVrelated extrahepatic diseases. There is evidence that successful eradication of chronic HCV infection with interferon-based therapy can ameliorate some extrahepatic complications. Achieving cure of chronic HCV has been associated with improvements in insulin resistance [10–12], reduced risk of diabetes [13], decreased incidence of stroke [14] and lymphoma [15], improvement in neurocognitive function [16], reduction in fatigue [17], and resolution of mixed cryoglobulinemia [18]. These studies were primarily conducted among HIV-uninfected patients, and it remains unclear if HIV differentially affects the impact of cured HCV on specific extrahepatic conditions. Successful treatment of chronic HCV also has been shown to reduce non-liver– related mortality. One cohort study of 530 chronic HCV-infected patients with advanced hepatic fibrosis or cirrhosis found that eradication of chronic HCV with interferon-based treatment significantly reduced rates of all-cause mortality [7], but this study excluded individuals with HIV coinfection. However, a separate cohort study of 1599 HIV/HCV–coinfected patients found that cure of chronic HCV with interferon plus ribavirin was associated with reductions in non-liver– related deaths as well as decreased HIV progression [8]. All-oral direct-acting antiviral (DAA) agents for the treatment of chronic HCV are now available and result in high (≥94%) rates of cure, regardless of HIV status, with minimal adverse effects [19– 22]. Because of their high costs, access to these drugs has been limited in many settings, often only restricted to patients with advanced liver fibrosis or cirrhosis [23–26]. However, if successful treatment of chronic HCV with DAA regimens is shown to improve HCV-related extrahepatic diseases and can reduce nonhepatic morbidity and mortality, including among HIV/HCV–coinfected individuals, then extrahepatic manifestations of chronic HCV may become a major E D I T O R I A L C O M M E N T A R Y

Treatment Outcomes of HCV Infection in People Living with HIV: A Case Series from a Single Center in Korea

The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment

Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care

Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years

Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study

Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010–2018

A simple, feasible, efficient and safe treatment strategy of sofosbuvir/velpatasvir for chronic HCV/HIV-1 coinfected patients regardless of HCV genotypes: a multicenter, open-label study in China

HCV‐HIV co‐infection in people who inject drugs: Barriers to treatment and cure of HCV infection in the era of DAAs, a prospective study in Athens, Greece

Impact of DAA Treatment for HCV on Hepatocellular Carcinoma in a Predominately African American Population

Long-Term Survival and Cancer Risk in the Hepatitis C Virus-Infected Patients After Antiviral Treatment: A Nationwide Cohort Study

Real-life data of hepatitis C treatment with direct acting antiviral therapy in persons injecting drugs or on opioid substitution therapy

Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis

Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan Natives

Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C

OP-3 HCV MICROELIMINATION PROGRAM IN HEMODIALYSIS PATIENTS: SUCCESS OF A MULTI-STAKEHOLDER PARTNERSHIP BASED ON A NATIONAL ERADICATION STRATEGY

Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.

Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study

Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients

Long-term Outcomes in Patients with Chronic Hepatitis C in the Current Era of Direct-Acting Antiviral Agents

Antiretroviral Therapy, Interferon Sensitivity, and Virologic Setpoint in Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Patients

Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon Versus Direct-Acting Agents